阿帕他胺治疗转移性去势敏感性前列腺癌:多中心真实世界ARON-3研究结果
ARON-3研究回顾性评估阿帕他胺治疗转移性去势敏感性前列腺癌的真实世界结局,纳入531例患者,中位总生存未达到,87%患者PSA下降≥90%,69%达到PSA≤0.2 ng/ml,年龄≥80岁患者3-4级乏力发生率高于年轻患者。
要点
- 阿帕他胺在真实世界中有效且可耐受,531例患者中位总生存未达到。
- 87%患者PSA下降≥90%,69%达到PSA≤0.2 ng/ml,与更长总生存显著相关。
- ≥80岁患者3-4级乏力发生率为19%,高于年轻患者的5%。
核心结论
- 阿帕他胺在真实世界环境中是转移性去势敏感性前列腺癌的有效且可耐受的治疗。
研究设计与样本
- ARON-3研究为回顾性多中心真实世界研究,纳入531例接受阿帕他胺治疗的转移性去势敏感性前列腺癌患者。
主要发现
- 214例(40%)患者为高瘤负荷疾病,56例(11%)有内脏转移。
- 中位总生存未达到;461例(87%)患者PSA下降≥90%,368例(69%)达到PSA≤0.2 ng/ml。
- 达到PSA下降≥90%或PSA≤0.2 ng/ml的患者中位总生存显著长于未达到这些反应者(p < 0.001)。
- ≥80岁患者3-4级乏力发生率为19%,年轻患者为5%;其他不良事件发生率在两个年龄组间相当。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Apalutamide (APA) is a treatment for metastatic castration-sensitive prostate cancer (mCSPC). In the ARON-3 study we investigated real-world experiences with APA treatment for mCSPC. METHODS: We retrospectively assessed real-world clinical outcomes for patients with mCSPC treated with APA in the ARON-3 study. Overall survival (OS) was calculated from APA initiation to death from any cause. PSA90 was defined as a prostate-specific antigen decline of ≥90% from baseline, and PSA0.2 as achievement of a PSA level ≤0.2 ng/ml. Data for adverse events were retrospectively collected from electronic and paper charts and categorized according to Common Terminology Criteria for Adverse Events v5.0. KEY FINDINGS AND LIMITATIONS: We included 531 patients with mCSPC treated with APA. High-volume disease was reported for 214 patients (40%), and 56 (11%) had visceral metastases. Median OS was not reached. PSA90 was experienced by 461 patients (87%) and PSA0.2 by 368 (69%). Median OS was significantly longer for patients with PSA90 or PSA0.2 than for subjects without these responses (p < 0.001). The incidence of grade 3-4 fatigue was higher among elderly patients (≥80 yr) than among younger patients (19% vs 5%), but the incidence of other adverse events was comparable between the age groups. CONCLUSIONS AND CLINICAL IMPLICATIONS: APA is an effective and tolerable treatment for mCSPC in the real-world setting. PATIENT SUMMARY: The ARON-3 project collects data for patients with prostate cancer treated in multiple centers worldwide to assess outcomes in the real-world setting. We analyzed data for patients with metastatic hormone-sensitive prostate cancer receiving apalutamide. Our results show that apalutamide is a safe and effective drug in the real-world setting as well as in clinical trials.
引用
- Santoni M, Büttner T, Rescigno P, et al. Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study. Eur Urol Oncol. 2024. PMID: 39613567. doi:10.1016/j.euo.2024.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。